Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 13

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
acorporeal membrane oxygenation; and

●The
                                            treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants,
                                            infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery,
                                            in order to selectively decrease pulmonary arterial pressure and improve right ventricular
                                            function

LungFit®
can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections
via delivery through a breathing mask or similar apparatus. Furthermore, the Company believes that there is a high unmet medical need
for patients suffering from certain severe lung infections that the LungFit® platform can potentially address. The Company’s
other areas of focus with the LungFit® platform beyond PPHN are  nontuberculous mycobacteria (“NTM”) lung infection and those with
various severe lung infections with underlying chronic obstructive pulmonary disease (“COPD”).

With
Beyond Air’s focus on NO and its effect on the human condition, the Company has two additional programs that do not utilize the
LungFit® system. Through the Company’s majority-owned affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)
NO is used to target solid tumors. The LungFit® platform is not utilized for the solid tumor indication due to the need
for ultra-high concentrations of gaseous nitric oxide (“UNO”). A proprietary delivery system has been developed that is designed
to safely deliver UNO in excess of 10,000 ppm directly to a solid tumor. This program has advanced to phase 1 human clinical trials.

On
November 4, 2021, Beyond Air reorganized its oncology business into a new private company called Beyond Cancer. Beyond Air’s preclinical
oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside
with Beyond Cancer. Beyond Air has 80% ownership in Beyond Cancer.

The
second program which does not utilize the LungFit® platform partially inhibits neuronal nitric oxide synthase (nNOS) in the brain
to treat neurological conditions. The first target indication is autism spectrum disorder (“ASD”). On June 15, 2023, the
Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem,
LTD. (the “University”) to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and